CabalettaBio (CABA) Upgradedby ZacksInvestmentResearch to Buy

CabalettaBio} stock has undergone multiple analysts rating changes in the recent past.  CabalettaBio Upgradedby ZacksInvestmentResearch on 10/8/2021. In a note to investors, the firm issued a new rating of Buy. The analysts previously had rating of Hold.

View More CabalettaBio (CABA) Upgradedby ZacksInvestmentResearch to Buy